The Global Market for Sepsis Therapeutics is Projected to Reach US$256.1 Million by 2022

Focus on Early Diagnosis, Efforts to Raise Awareness & Inclusion in National Health Priority Programs Drive the Sepsis Therapeutics Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Sepsis Therapeutics market. The global market for Sepsis Therapeutics is projected to reach US$256.1 million by 2022, driven by the growing focus on implementing international guidelines on sepsis prevention and management; efforts taken to raise awareness of this common yet poorly understood disease condition; and clinical development of new drug candidates.  

  

Sepsis or Systemic Inflammatory Response Syndrome (SIRS) represents a life-threatening medical condition caused by abnormal host immune response to infection. Uncontrolled sepsis or septic shock results in multiple organ dysfunction, rapidly leading to death. Sepsis is an often overlooked condition despite its very high frequency. Sepsis-associated mortality and its prevalence are higher than heart attack, or any form of cancer. Rising prevalence of sepsis is attributable to the growing number of surgeries and hospital-acquired infections; growing threat of infectious diseases; and rapidly aging population with compromised immune system and metabolism. Furthermore, increasing research and clinical trials in this area will support future growth in the market. Factors restraining market growth include the lack of standard sepsis management protocol, an overwhelming lack of awareness on the subject, and shortage of skilled staff with expertise on sepsis. Current treatment options for sepsis are confined to antibiotics that target the specific pathogen, and subsequent patient monitoring, symptom management and support. There is no drug currently available on the market that addresses septic shock exclusively.  Xigris (by Eli Lily) was the only drug approved in 2001 for sepsis; however, in 2011, the drug was withdrawn from the market after extensive trial results showed adverse side effects and drug efficacy concerns.

The high unmet market need therefore offers significant potential for sepsis therapeutics players and potential market entrants. The sepsis therapeutics market is dominated by clinical-stage pharmaceutical companies with drug candidates still in preclinical R&D and early clinical trials. InflaRx, Asahi Kasei Pharma America, and T2 Biosystems represent a few companies with late Phase II and Phase III products. Future growth of the market is expected to be dominated by novel, first-in-class candidates such as ART-123 (by Asahi Kasei Pharma America), which will most likely be indicated for sepsis-induced acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). Once launched, ART-123 is estimated to dominate the market till 2019 due to lack of competition and enjoy high pricing due to its first-in-class status. Other major pipeline drugs include ALT-836 anticoagulant and recombinant human alkaline phosphatase (RecAP) by Altor Bioscience, another RecAP by AM-Pharma; LB-1148 (tranexamic acid) by Leading Biosciences; and the humanized anti-complement monoclonal antibody IFX-1 by InflaRx.

As stated by the new market research report on Sepsis Therapeutics, the United States is forecast to emerge as the largest market worldwide. Excluding the U.S., Rest of World ranks as the fastest growing market with a robust CAGR of 75.5% over the analysis supported by the high number of sepsis infections, and the need for effective therapeutics.

Major players covered in the report include Adrenomed AG, AM-Pharma B.V., Aridis Pharmaceuticals, Inc., Asahi Kasei Pharma America, Astellas Pharma Inc., Bristol-Myers Squibb, Chong Kun Dang BiO Corporation, Endacea Inc., InflaRx GmbH, Opsona Therapeutics Ltd.., Opsonix, Inc., T2 Biosystems Inc., TaiRx Inc., and TiGenix NV, among others.

The research report titled "Sepsis Therapeutics: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, growth drivers, mergers and acquisitions, and other strategic industry activities of major companies worldwide. The report provides market estimates and projections for geographic markets of the US and Rest of World.  

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.